Database→PEG-MGF

Tier 4MuscleRecoveryInjuryPREMIUM

PEG-MGF

PEG-MGF (Pegylated Mechano Growth Factor; Pegylated IGF-1Ec E-domain Peptide)

Not FDA-approved for any indication. No approved drug status in any jurisdiction. Sold as research chemical only; illegal for human use in the USA. Prohibited under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) since 2005. This prohibition applies at all times, both in and out of competition.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic analog of MGF, the 24-amino-acid E-domain peptide of the IGF-1Ec splice variant naturally released in skeletal muscle in response to mechanical damage. PEGylation extends the half-life from minutes to an estimated 24 to 72 hours. MGF has been WADA-prohibited under S2 since 2005. No human interventional trial of PEG-MGF or exogenous MGF has been published. Animal evidence includes satellite cell activation, cardiac protection post-infarction in sheep (Carpenter 2008: 35% less compromised myocardium), and progenitor cell increases in ALS and DMD mouse models. Observational human data shows blunted endogenous MGF expression in elderly versus young men after resistance exercise (Hameed 2003, n=34). The IGF-1 pathway oncology risk is a meaningful theoretical safety concern.

🔒

Full Profile: Premium Members Only

The complete PEG-MGF profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use